Press releasePress releasePHN-00022026-10-29 09:30 CT
Retatrutide phase 3 topline results reported by sponsor
Source · Company press release
TLDR
Sponsor reports topline weight-loss outcomes; full data not yet peer reviewed.
Why it matters Editorial
First phase 3 look at a triple agonist.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.